127 related articles for article (PubMed ID: 38448368)
1. Exploration of YBX1 role in the prognostic value and immune characteristics by single-cell and bulk sequencing analysis for liver hepatocellular carcinoma.
Zhang Q; Zhu B; Yang H; Li F; Qu Y; Lu L; Zhang Q
J Gene Med; 2024 Mar; 26(3):e3680. PubMed ID: 38448368
[TBL] [Abstract][Full Text] [Related]
2. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
Liu Z; Zhao P
J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
[TBL] [Abstract][Full Text] [Related]
4. Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment.
Liu L; Zhang M; Cui N; Liu W; Di G; Wang Y; Xi X; Li H; Shen Z; Gu M; Wang Z; Jiang S; Liu B
PLoS One; 2024; 19(4):e0298004. PubMed ID: 38635528
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of N
Zhu HX; Lu WJ; Zhu WP; Yu S
J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
[TBL] [Abstract][Full Text] [Related]
6. A Model of Basement Membrane-Associated Gene Signature Predicts Liver Hepatocellular Carcinoma Response to Immune Checkpoint Inhibitors.
Shen J; Wei Z; Lv L; He J; Du S; Wang F; Wang Y; Ni L; Zhang X; Pan F
Mediators Inflamm; 2023; 2023():7992140. PubMed ID: 37152370
[TBL] [Abstract][Full Text] [Related]
7. A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility.
Liu Y; Meng J; Ruan X; Wei F; Zhang F; Qin X
Sci Rep; 2024 Jan; 14(1):746. PubMed ID: 38185671
[TBL] [Abstract][Full Text] [Related]
8. A signature based on neutrophil extracellular trap-related genes for the assessment of prognosis, immunoinfiltration, mutation and therapeutic response in hepatocellular carcinoma.
Wang L; Wang Q; Li Y; Qi X; Fan X
J Gene Med; 2024 Jan; 26(1):e3588. PubMed ID: 37715643
[TBL] [Abstract][Full Text] [Related]
9. Anoikis-related signature in liver hepatocellular carcinoma defines the YBX1/SPP1 axis by machine learning strategies and valid experiments.
Ma Y; She X; Zhao J; Liu S; Li C; Wang Q
J Gene Med; 2023 Oct; 25(10):e3516. PubMed ID: 37118998
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.
Ding D; Wang D; Qin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299
[TBL] [Abstract][Full Text] [Related]
11. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
Jin W; Wang G; Dong M; Wang X
Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
[TBL] [Abstract][Full Text] [Related]
12. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
13. High expression of RNF31 is associated with tumor immune cell infiltration and leads to poor prognosis in liver hepatocellular carcinoma.
Xi G; Cheng R; Liang L; Che N; Wang Y; Zhao N; Liang X; Shao B; Zhao X; Zhang D
Sci Rep; 2023 Apr; 13(1):6957. PubMed ID: 37117215
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin V is correlated with the prognosis and tumor microenvironment in liver cancer.
Liu J; Zhang W; Wang Z; Wang Y; Li T; Wang Y; Ding J; Ning B
Mol Carcinog; 2024 Mar; 63(3):400-416. PubMed ID: 38051285
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker.
Zhao X; Liu Y; Yu S
Biochim Biophys Acta Mol Basis Dis; 2017 Jul; 1863(7):1805-1816. PubMed ID: 28428004
[TBL] [Abstract][Full Text] [Related]
16. Fanconi Anemia Complementary Group A (FANCA) Facilitates the Occurrence and Progression of Liver Hepatocellular Carcinoma.
Huang FD; Zhong YP; Sun GY; Xu QJ; Xing ZY; Chen KH; Liao LS; Dong MY
Dig Dis Sci; 2024 Mar; 69(3):1035-1054. PubMed ID: 38282187
[TBL] [Abstract][Full Text] [Related]
17. Prognostic prediction and multidimensional dissections of a macrophages M0-related gene signature in liver cancer.
Xu X; Wang J
Front Endocrinol (Lausanne); 2023; 14():1153562. PubMed ID: 37033261
[TBL] [Abstract][Full Text] [Related]
18. Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma.
Qiu C; Li Z; Cao W; Cai X; Ye L; Zhang C; Ma Y; Wang X; Yang Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34435618
[TBL] [Abstract][Full Text] [Related]
19. Exploring the role of CDCA4 in liver hepatocellular carcinoma using bioinformatics analysis and experiments.
Liang C; Long K; Zheng W; Zhong R; Li Z; Zhu S; Gu S; Zhu C; Yang Y
Medicine (Baltimore); 2024 May; 103(18):e38028. PubMed ID: 38701314
[TBL] [Abstract][Full Text] [Related]
20. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
